Tipranks Press Release.
Qiagen (NYSE:QGEN) received shareholder approval at an Extraordinary General Meeting for Jonathan M. Pratt to become CEO and Managing Director. Jonathan M. Pratt is set to succeed Thierry Bernard in the top leadership role following the Extraordinary General Meeting vote. The board decision formalizes a transition at the top of Qiagen's management structure, shifting responsibilities from Thierry Bernard to Pratt. The leadership handover from Thierry Bernard to Jonathan M. Pratt is only one...
Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3% return over three years, Qiagen now asks investors to judge whether that run is backed by the cash its business can generate over time. New projects in areas such as precision medicine, clinical...
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Qiagen (QGEN) said Wednesday it agreed to be acquired by EQT Private Equity for 46.50 euros ($52.26)
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Qiagen (QGEN) shares jump on takeover talk as PE firms and a US molecular testing buyer eye a deal at a “realistic premium.” Get the latest update.
This is the newest page. Registered accounts read further back.